Volume 24 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(6): 957-961
CHEN Dongmei, XUAN Ling, LI Jingjing, WANG Maolin, LI Xiaoxi. Effect of alirocumab combined with statin therapy on short-term major adverse cardiovascular events in patients with acute myocardial infarction after percutaneous coronary intervention[J]. Chinese Journal of General Practice, 2026, 24(6): 957-961. doi: 10.16766/j.cnki.issn.1674-4152.004530
Citation: CHEN Dongmei, XUAN Ling, LI Jingjing, WANG Maolin, LI Xiaoxi. Effect of alirocumab combined with statin therapy on short-term major adverse cardiovascular events in patients with acute myocardial infarction after percutaneous coronary intervention[J]. Chinese Journal of General Practice, 2026, 24(6): 957-961. doi: 10.16766/j.cnki.issn.1674-4152.004530
shu

Effect of alirocumab combined with statin therapy on short-term major adverse cardiovascular events in patients with acute myocardial infarction after percutaneous coronary intervention

doi: 10.16766/j.cnki.issn.1674-4152.004530
  • 1.

    Department of Cardiology, the Third People's Hospital of Bengbu City, Bengbu, Anhui 233000, China

Funds:

 AHWJ2024BAi20001

  • Received Date: 2025-09-25
    Available Online: 2026-11-10
    Abstract
  •   Objective  To investigate the effect of alirocumab combined with statin therapy on the short-term prognosis of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), and to identify independent predictors of major adverse cardiovascular events (MACE).  Methods  A total of 120 AMI patients who underwent PCI between January 2022 and December 2023 were retrospectively enrolled and divided into an alirocumab group and a control group (n=60 each). The control group received standard secondary prevention therapy, whereas the alirocumab group received additional alirocumab treatment. Lipid profiles, renal function parameters, and CRP levels were assessed at baseline and 14 days after treatment. Patients were followed up for 6 months to record occurrence of MACE. Kaplan-Meier analysis was used to compare cumulative event rates, and Cox proportional hazards regression models were applied to identify independent predictors of MACE.  Results  Compared with the control group, the alirocumab group showed significantly lower levels of TC, TG, low density lipoprotein cholesterol (LDL-C), and CRP, as well as significantly higher levels of high-density lipoprotein cholesterol (HDL-C) levels at 14 days after treatment (P < 0.05). Serum creatinine and blood urea nitrogen levels were also significantly reduced (P < 0.05), while ALT and AST levels showed no significant differences between the two groups (P>0.05). During the 6-month follow-up period, the incidence of MACE was significantly lower in the alirocumab group [10.0% (6/60) vs. 31.7% (19/60), P < 0.05]. Cox regression analysis identified alirocumab use as an independent protective factor for MACE (HR=0.451, 95% CI: 0.271-0.762, P=0.029), whereas elevated baseline LDL-C, CRP, and serum creatinine levels were independent risk factors (P < 0.05).  Conclusion  The addition of alirocumab to standard antiplatelet and statin therapy can further improve lipid profiles, reduce inflammation, preserve renal function, and decrease the risk of short-term MACE in patients with AMI after PCI.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    BISCAGLIA S, GUIDUCCI V, ESCANED J, et al. Complete or culprit-only PCI in older patients with myocardial infarction[J]. N Engl J Med, 2023, 389(10): 889-898. doi: 10.1056/NEJMoa2300468
    [2]
    BÖHM F, MOGENSEN B, ENGSTRØM T, et al. FFR-guided complete or culprit-only PCI in patients with myocardial infarction[J]. N Engl J Med, 2024, 390(16): 1481-1492. doi: 10.1056/NEJMoa2314149
    [3]
    OZAKI Y, TOBE A, ONUMA Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026[J]. Cardiovasc Interv Ther, 2026, 41(2): 209-255. doi: 10.1007/s12928-025-01229-z
    [4]
    ELGENDY I Y, MAHTTA D, PANIAGUA D. Multivessel PCI for acute myocardial infarction: where do we stand after the COMPLETE trial[J]. Curr Cardiol Rep, 2020, 22(9): 97. DOI: 10.1007/s11886-020-01340-y.
    [5]
    WARNER E D, ULLAH W, FARBER J, et al. PCI for acute myocardial infarction in patients with a pre-existing LVAD, does it improve survival[J]. Artif Organs, 2023, 47(4): 761-769. doi: 10.1111/aor.14444
    [6]
    LIBBY P. Mechanisms of acute coronary syndromes and their implications for therapy[J]. N Engl J Med, 2013, 368(21): 2004-2013. doi: 10.1056/NEJMra1216063
    [7]
    黄光华, 张金子, 张权宇, 等. 急性心肌梗死患者围术期急诊经皮冠状动脉介入治疗联合糖蛋白Ⅱb/Ⅲa抑制剂后应用P2Y12受体拮抗剂有效性与安全性分析[J]. 临床军医杂志, 2021, 49(5): 514-516.

    Huang G H, Zhang J Z, Zhang Q Y, et al. Analysis of the efficacy and safety of P2Y12 receptor antagonists after perioperative emergency percutaneous coronary intervention combined with glycoprotein Ⅱb/Ⅲa inhibitors in patients with acute myocardial infarction[J]. Clinical Journal of Medical Officers, 2021, 49(5): 514-516.
    [8]
    管晶晶, 时鹏, 李保伍, 等. 颈动脉粥样硬化斑块超声联合血脂指标对心血管疾病的预测价值评估[J]. 中华全科医学, 2022, 20(8): 1376-1379. doi: 10.16766/j.cnki.issn.1674-4152.002601

    Guan J J, Shi P, Li B W, et al. Predictive value of carotid atherosclerotic plaque ultrasound combined with blood lipid indicators for cardiovascular diseases[J]. Chinese Journal of General Practice, 2022, 20(8): 1376-1379. doi: 10.16766/j.cnki.issn.1674-4152.002601
    [9]
    侯丽君, 刘世杰. ApoE基因多态性对阿利西尤单抗调脂疗效影响的分析[J]. 中国临床药理学杂志, 2024, 40(13): 1851-1854.

    Hou L J, Liu S J. Influence of ApoE gene polymorphism on the lipid-lowering efficacy of alirocumab[J]. The Chinese Journal of Clinical Pharmacology, 2024, 40(13): 1851-1854.
    [10]
    张卫丰, 马海龙, 张金玲. PCSK9抑制剂对ST段抬高型急性心肌梗死PCI后炎症水平和心室重构的影响[J]. 实用医学杂志, 2024, 40(15): 2142-2147.

    Zhang W F, Ma H L, Zhang J L. Effects of PCSK9 inhibitors on inflammatory levels and ventricular remodeling after PCI in patients with ST-segment elevation myocardial infarction[J]. The Journal of Practical Medicine, 2024, 40(15): 2142-2147.
    [11]
    陈仁亮. 急诊PCI术后早期应用PCSK9抑制剂对心脏保护作用的临床研究[D]. 呼和浩特: 内蒙古医科大学, 2024.

    Chen R L. Clinical study on the cardioprotective effect of early application of PCSK9 inhibitors after emergency PCI[D]. Hohhot: Inner Mongolia Medical University, 2024.
    [12]
    OESTERLE A, LAUFS U, LIAO J K. Pleiotropic effects of statins on the cardiovascular system[J]. Circ Res, 2017, 120(1): 229-243. doi: 10.1161/CIRCRESAHA.116.308537
    [13]
    VIOLI F, CALVIERI C, FERRO D, et al. Statins as antithrombotic drugs[J]. Circulation, 2013, 127(2): 251-257. doi: 10.1161/CIRCULATIONAHA.112.145334
    [14]
    JIANG Y, ZHONG Q, LI W, et al. Efficacy and safety of PCSK9 inhibitors, potent statins and their combination in hyperlipidemia: a systematic review and meta-analysis[J]. Front Pharmacol, 2024, 15: 1366893. DOI: 10.3389/fphar.2024.1366893.
    [15]
    THYGESEN K, ALPERT J S, JAFFE A S, et al. Fourth universal definition of myocardial infarction (2018)[J]. J Am Coll Cardiol, 2018, 72(18): 2231-2264. doi: 10.1016/j.jacc.2018.08.1038
    [16]
    张玲姬, 吴培颖, 赵薇. 匹伐他汀与阿托伐他汀对PCI术后急性心肌梗死患者血脂、血管内皮功能、炎性因子的影响[J]. 河北医药, 2023, 45(20): 3085-3089.

    Zhang L J, Wu P Y, Zhao W. Effects of pitavastatin and atorvastatin on blood lipid levels, vascular endothelial function and inflammatory factors in patients with acute myocardial infarction after PCI[J]. Hebei Medical Journal, 2023, 45(20): 3085-3089.
    [17]
    曲曼青, 张喜军, 苏轶楣, 等. 匹伐他汀联合心肺康复训练对老年心肌梗死患者PCI术后疗效及血脂水平的影响[J]. 中国老年学杂志, 2023, 43(14): 3338-3342.

    Qu M Q, Zhang X J, Su Y M, et al. Effects of pitavastatin combined with cardiopulmonary rehabilitation training on clinical efficacy and blood lipid levels in elderly patients with myocardial infarction after PCI[J]. Chinese Journal of Gerontology, 2023, 43(14): 3338-3342.
    [18]
    SCHWARTZ G G, STEG P G, SZAREK M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174
    [19]
    NICHOLLS S J, PURI R S, ANDERSON T, et al. Effect of evolocumab on coronary plaque composition[J]. J Am Coll Cardiol, 2018, 72(17): 2012-2021. doi: 10.1016/j.jacc.2018.06.078
    [20]
    TOMMASINO A, D'ASCENZO F, GILI S, et al. Evolving role of P2Y12 inhibitors in ST-segment elevation myocardial infarction: focus on thrombus burden and microvascular obstruction[J]. Rev Cardiovasc Med, 2024, 25(4): 106.
    [21]
    陈伟, 周静. 前列腺素E1预防急性心肌梗死患者PCI术后肾功能损伤的价值[J]. 医学临床研究, 2022, 39(9): 1318-1321.

    Chen W, Zhou J. Value of prostaglandin E1 in preventing renal function injury after PCI in patients with acute myocardial infarction[J]. Journal of Clinical Research, 2022, 39(9): 1318-1321.
    [22]
    周海涛, 毕剑波, 陈艳霞. 持续肾替代治疗改善急性心肌梗死合并心肾功能不全患者PCI术后心肾功能和预后的作用[J]. 中国急救复苏与灾害医学杂志, 2020, 15(11): 1244-1248.

    Zhou H T, Bi J B, Chen Y X. Effect of continuous renal replacement therapy on cardiac and renal function and prognosis in patients with acute myocardial infarction complicated with cardiorenal insufficiency after PCI[J]. Chinese Journal of Emergency Resuscitation and Disaster Medicine, 2020, 15(11): 1244-1248.
    [23]
    樊小雨, 张柳, 许志萍. 急性心肌梗死患者PCI术后血清BNP、CRP的表达及对预后的影响[J]. 中国循证心血管医学杂志, 2024, 16(2): 224-226.

    Fan X Y, Zhang L, Xu Z P. Expression of serum BNP and CRP and their influence on prognosis in patients with acute myocardial infarction after PCI[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2024, 16(2): 224-226.
    [24]
    刘喜雷, 侯雨岩, 王志方, 等. CRP/ApoA1预测老年急性心肌梗死病人PCI术预后的临床价值[J]. 中西医结合心脑血管病杂志, 2024, 22(15): 2816-2819.

    Liu X L, Hou Y Y, Wang Z F, et al. Clinical value of CRP/ApoA1 in predicting the prognosis of elderly patients with acute myocardial infarction after PCI[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2024, 22(15): 2816-2819.
    [25]
    于中玉, 贺文帅. 急性心肌梗死患者经皮冠状动脉介入术后血脂达标率、影响因素及预后分析[J]. 心脑血管病防治, 2024, 24(8): 54-56.

    Yu Z Y, He W S. Analysis of lipid goal attainment rate, influencing factors and prognosis in patients with acute myocardial infarction after percutaneous coronary intervention[J]. Prevention and Treatment of Cardio-Cerebral-Vascular Disease, 2024, 24(8): 54-56.
    [26]
    RIDKER P M, LIBBY P, MACFADYEN J G, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)[J]. Eur Heart J, 2018, 39(38): 3499-3507. doi: 10.1093/eurheartj/ehy310
    • Relative Articles
    • Supplements(0)
    • Cited By

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (18) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return